Loading
A phase 3 trial of Gallium-68 DOTATATE in Neuroendocrine tumours, run by Centre de recherche du Centre hospitalier universitaire de Sherbrooke, with a status the registry has not verified recently.
68Ga-DOTA-TATE PET/CT Imaging in NETs is a phase 3 interventional study registered as NCT04847505 by Centre de recherche du Centre hospitalier universitaire de Sherbrooke, with 5000 participants planned, started 2020-01-01 and due to reach its primary completion in 2025-12-31. Interventions recorded: 68Ga-DOTA-TATE. Conditions recorded: Neuroendocrine Tumors.
Linked to the drug Gallium-68 DOTATATE because the registry names it among its interventions and Neuroendocrine tumours among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gallium-68 DOTATATE (and Cu-64 DOTATATE) and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/